FIBROMUN (L19-TNF)

Fibromun (L19-TNF) is a fully-human vascular targeting immunocytokine, currently being tested in clinical trials in patients with cancer. It consists of the anti-EDB human antibody L19, fused to human TNF, a strong pro-inflammatory cytokine. Recombinant TNF (Beromun TM, Boehringer Ingelheim) has so far been approved only for clinical applications in the isolated limb perfusion setting.

Because of its impressive tumor targeting and therapeutic performance in animal models of cancer, Fibromun is being studied in clinical trials which feature both the systemic administration of this biopharmaceutical to a large population of patients and to melanoma patients in the isolated limb perfusion setting.

SELECTED REFERENCES
Balza et al. (2006) Clin. Cancer Res., 12, 2575-2582;
Borsi et al. (2003) Blood, 102, 4384-4392;